Pub Date : 2024-07-08DOI: 10.21294/1814-4861-2024-23-3-178-185
E. A. Toneev, A. A. Firstov, D. I. Nuretdinov, E. Y. Savenko, E. P. Anokhina, A. A. Martynov, Yulia A. Karabanova
Purpose: To demonstrate treatment outcomes in two patients with small cell esophageal cancer. Cases reports. Patient M. was assigned to receive polychemotherapy (PC H) composed of etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days, followed by chemoradiotherapy (CRT). The patient received 1 cycle of PCT , which was well tolerated. Then, the patient received a cycle of 3D-conformal radiation therapy concurrently with 2 cycles of chemotherapy: etoposide 120 mg/m2 + cisplatin 80 mg/m2. Chemoradiotherapy was well tolerated. Dysphagia regression to grade I was observed. Currently, the patient continues to receive treatment (etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days) and tolerates it well. Patient A. was assigned to receive PCT with etoposide 120 mg/m2 + cisplatin 80 mg/m2. After 4 cycles of PCT , the follow-up CT images revealed disease progression (enlarged retroperitoneal lymph nodes). The patient underwent external bean radiation therapy to the primary tumor. Radiotherapy was relatively well tolerated. The patient underwent the course of radiation therapy relatively satisfactorily. Due to the progression of the disease, symptomatic treatment was assigned. The patient died 9 months after diagnosis. Conclusion. Small cell carcinoma of the esophagus is a rare histological type with poor prognosis. Concurrent platinum-based chemoradiotherapy allows achievement of stable disease and disease control.
{"title":"Small cell cancer of the esophagus, treatment outcomes of a rare histological type","authors":"E. A. Toneev, A. A. Firstov, D. I. Nuretdinov, E. Y. Savenko, E. P. Anokhina, A. A. Martynov, Yulia A. Karabanova","doi":"10.21294/1814-4861-2024-23-3-178-185","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-178-185","url":null,"abstract":"Purpose: To demonstrate treatment outcomes in two patients with small cell esophageal cancer. Cases reports. Patient M. was assigned to receive polychemotherapy (PC H) composed of etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days, followed by chemoradiotherapy (CRT). The patient received 1 cycle of PCT , which was well tolerated. Then, the patient received a cycle of 3D-conformal radiation therapy concurrently with 2 cycles of chemotherapy: etoposide 120 mg/m2 + cisplatin 80 mg/m2. Chemoradiotherapy was well tolerated. Dysphagia regression to grade I was observed. Currently, the patient continues to receive treatment (etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days) and tolerates it well. Patient A. was assigned to receive PCT with etoposide 120 mg/m2 + cisplatin 80 mg/m2. After 4 cycles of PCT , the follow-up CT images revealed disease progression (enlarged retroperitoneal lymph nodes). The patient underwent external bean radiation therapy to the primary tumor. Radiotherapy was relatively well tolerated. The patient underwent the course of radiation therapy relatively satisfactorily. Due to the progression of the disease, symptomatic treatment was assigned. The patient died 9 months after diagnosis. Conclusion. Small cell carcinoma of the esophagus is a rare histological type with poor prognosis. Concurrent platinum-based chemoradiotherapy allows achievement of stable disease and disease control.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":"117 42","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141667666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-08DOI: 10.21294/1814-4861-2024-23-3-168-177
M. I. Makarova, D. A. Davydova, E. N. Bogush-Vishnevskaya, A. A. Shcherbakova, S. V. Gamayunov, A. M. Ermolaeva, V. Grishakov, I. S. Shumskaia
Digital papillary adenocarcinoma (DPA ) is a rare malignant neoplasm of sweat glands, which was first described by Helwig in 1979 and then classified by Kao in 1987. This disease most often occurs in men aged 50–70 years and is characterized by a relatively favorable prognosis. In most cases, radical excision of the tumor leads to cure. However, 14–47 % of patients develop distant metastases with predominant lung involvement (70 %). The study of etiology and pathogenesis of this rare cancer and its molecular genetic profile seems to be interesting. Currently, there is no clear approach to the treatment of metastatic DPA , but sporadic cases of using chemotherapy have been reported. Aim of the study: to analyze current data on the pathogenesis of DPA , diagnostic features and treatment methods used, as well as to present the first clinical case of treatment of disseminated digital carcinoma with immune checkpoint inhibitors described in scientific literature. Material and Methods. A search of available literature published in Medline, Pubmed, etc. databases from 1984 to 2023 was performed, 21 sources were included in this review. Clinical Case Description. We present a rare case of metastatic digital papillary carcinoma in a 23-year-old male with disease manifestation at the age of 14 years. Lack of vigilance and awareness of oncologists and morphologists did not allow timely diagnosis of malignancy, even in case of 3 local recurrences of the disease. Only biopsy of a metastatic lung nodule with histological and IHC examination (of archival and new material) made it possible to make a correct diagnosis. This case revealed 2 potential targets that could be used for disease control: androgen receptor positive expression and PD -L1 expression with CPS =20. The use of immune response checkpoint inhibitors (ipilimumab + nivolumab) resulted in partial response followed by stable disease.
{"title":"A rare tumour – metastatic digital papillary adenocarcinoma: literature review, clinical case of successful therapy","authors":"M. I. Makarova, D. A. Davydova, E. N. Bogush-Vishnevskaya, A. A. Shcherbakova, S. V. Gamayunov, A. M. Ermolaeva, V. Grishakov, I. S. Shumskaia","doi":"10.21294/1814-4861-2024-23-3-168-177","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-168-177","url":null,"abstract":"Digital papillary adenocarcinoma (DPA ) is a rare malignant neoplasm of sweat glands, which was first described by Helwig in 1979 and then classified by Kao in 1987. This disease most often occurs in men aged 50–70 years and is characterized by a relatively favorable prognosis. In most cases, radical excision of the tumor leads to cure. However, 14–47 % of patients develop distant metastases with predominant lung involvement (70 %). The study of etiology and pathogenesis of this rare cancer and its molecular genetic profile seems to be interesting. Currently, there is no clear approach to the treatment of metastatic DPA , but sporadic cases of using chemotherapy have been reported. Aim of the study: to analyze current data on the pathogenesis of DPA , diagnostic features and treatment methods used, as well as to present the first clinical case of treatment of disseminated digital carcinoma with immune checkpoint inhibitors described in scientific literature. Material and Methods. A search of available literature published in Medline, Pubmed, etc. databases from 1984 to 2023 was performed, 21 sources were included in this review. Clinical Case Description. We present a rare case of metastatic digital papillary carcinoma in a 23-year-old male with disease manifestation at the age of 14 years. Lack of vigilance and awareness of oncologists and morphologists did not allow timely diagnosis of malignancy, even in case of 3 local recurrences of the disease. Only biopsy of a metastatic lung nodule with histological and IHC examination (of archival and new material) made it possible to make a correct diagnosis. This case revealed 2 potential targets that could be used for disease control: androgen receptor positive expression and PD -L1 expression with CPS =20. The use of immune response checkpoint inhibitors (ipilimumab + nivolumab) resulted in partial response followed by stable disease.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141668885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-07DOI: 10.21294/1814-4861-2024-23-3-159-167
A. N. Useinova, V. B. Kaliberdenko, S. P. Maryanenko, J. M. Al-Nsour, A. A. Korenkova
Purpose of the study: to provide current data on pharmacotherapy of hormone-dependent breast cancer (hdBC) and to consider the feasibility of introducing new hormone therapy drugs for breast cancer into clinical practice. Material and Methods. We analyzed 80 publications available Pubmed, Springer, Cochrane Library, etc. concerning the study of pharmacological characteristics of various groups of drugs for the treatment of hdBC, of which 49 were included in this review. Results. Currently, there are several approaches to the treatment of hdBC. Selective estrogen receptor modulators and aromatase inhibitors are the most studied and frequently used drugs. The cyclin-dependent kinase 4/6 inhibitors can be present in both the first- and second-line therapy. Currently, close attention is paid to the development of new drugs based on genomic profiling of the tumor, which is the standard of treatment for hdBC, and contributes to the personalization of therapy. Conclusion. Further development of drugs holds great promise for increasing overall survival and more accurate prognosis, response to conventional systemic therapy, and individualization of pharmacotherapy for hdBC. However, further research and development of new drugs is required. In this regard, the introduction of oral selective estrogen receptor degraders into practice and the development of new drugs that block estrogen-dependent and independent signaling to estrogen receptors are the most promising trends.
{"title":"A review of endocrine therapy for hormone-dependent breast cancer","authors":"A. N. Useinova, V. B. Kaliberdenko, S. P. Maryanenko, J. M. Al-Nsour, A. A. Korenkova","doi":"10.21294/1814-4861-2024-23-3-159-167","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-159-167","url":null,"abstract":"Purpose of the study: to provide current data on pharmacotherapy of hormone-dependent breast cancer (hdBC) and to consider the feasibility of introducing new hormone therapy drugs for breast cancer into clinical practice. Material and Methods. We analyzed 80 publications available Pubmed, Springer, Cochrane Library, etc. concerning the study of pharmacological characteristics of various groups of drugs for the treatment of hdBC, of which 49 were included in this review. Results. Currently, there are several approaches to the treatment of hdBC. Selective estrogen receptor modulators and aromatase inhibitors are the most studied and frequently used drugs. The cyclin-dependent kinase 4/6 inhibitors can be present in both the first- and second-line therapy. Currently, close attention is paid to the development of new drugs based on genomic profiling of the tumor, which is the standard of treatment for hdBC, and contributes to the personalization of therapy. Conclusion. Further development of drugs holds great promise for increasing overall survival and more accurate prognosis, response to conventional systemic therapy, and individualization of pharmacotherapy for hdBC. However, further research and development of new drugs is required. In this regard, the introduction of oral selective estrogen receptor degraders into practice and the development of new drugs that block estrogen-dependent and independent signaling to estrogen receptors are the most promising trends.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 65","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141671307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-07DOI: 10.21294/1814-4861-2024-23-3-133-149
A. Nevolskikh, V. A. Avdeenko, I. P. Reznik, T. P. Pochuev, R. F. Zibirov, S. Ivanov, A. Kaprin
The study aimed to perform a systematic review of the literature on surgical treatment for right colon cancer (RCC) with complete mesocolic excision (CME) and D2/D3 lymph node dissection (LND). Material and Methods. A literature review was performed for studies published between 2013 and 2023 by the online resources from the official Web sites of the societies/panels and PubMed database. Sources included guidelines, meta-analyses, randomized and nonrandomized clinical studies, guidelines by European Society of Medical Oncology, the Japanese Society for Cancer of the Colon and Rectum, and the National Comprehensive Cancer Network, Russian clinical guidelines. Results. CME significantly improved both immediate and long-term treatment results, which was confirmed by numerous meta-analyses. The extent of LND remains one of the most controversial issues in RCC. For many Asian surgeons, D3 LND is the standard procedure for the treatment of RCC, whereas the European approach is more conservative and apical lymph node dissection is not mandatory. There are also large differences in understanding the extent of D3 LND in RCC. Most surgeons understand this term as dissection of adipose tissue along the anterior and lateral surface of the superior mesenteric vein, however, there are authors who perform circular dissection along the superior mesenteric vessels, considering this extent of surgery to be the most radical. Conclusion. It is necessary to standardize methods and effective criteria for quality control of CME for RCC and LND. In this case, external independent assessment of the quality of surgical intervention is important. There is also currently a growing number of studies in which intraoperative fluorescence imaging makes it possible to better visualize the location of the apical lymph nodes and individualize LND.
{"title":"Surgical treatment of right colon cancer","authors":"A. Nevolskikh, V. A. Avdeenko, I. P. Reznik, T. P. Pochuev, R. F. Zibirov, S. Ivanov, A. Kaprin","doi":"10.21294/1814-4861-2024-23-3-133-149","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-133-149","url":null,"abstract":"The study aimed to perform a systematic review of the literature on surgical treatment for right colon cancer (RCC) with complete mesocolic excision (CME) and D2/D3 lymph node dissection (LND). Material and Methods. A literature review was performed for studies published between 2013 and 2023 by the online resources from the official Web sites of the societies/panels and PubMed database. Sources included guidelines, meta-analyses, randomized and nonrandomized clinical studies, guidelines by European Society of Medical Oncology, the Japanese Society for Cancer of the Colon and Rectum, and the National Comprehensive Cancer Network, Russian clinical guidelines. Results. CME significantly improved both immediate and long-term treatment results, which was confirmed by numerous meta-analyses. The extent of LND remains one of the most controversial issues in RCC. For many Asian surgeons, D3 LND is the standard procedure for the treatment of RCC, whereas the European approach is more conservative and apical lymph node dissection is not mandatory. There are also large differences in understanding the extent of D3 LND in RCC. Most surgeons understand this term as dissection of adipose tissue along the anterior and lateral surface of the superior mesenteric vein, however, there are authors who perform circular dissection along the superior mesenteric vessels, considering this extent of surgery to be the most radical. Conclusion. It is necessary to standardize methods and effective criteria for quality control of CME for RCC and LND. In this case, external independent assessment of the quality of surgical intervention is important. There is also currently a growing number of studies in which intraoperative fluorescence imaging makes it possible to better visualize the location of the apical lymph nodes and individualize LND.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 59","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141671405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-07DOI: 10.21294/1814-4861-2024-23-3-150-158
P. A. Lushnikova, E. Sukhikh, Z. Startseva
The aim of the study was to analyze and summarize the available literature data on the modern radiotherapy techniques, indications for radiotherapy (preoperative, radical, postoperative radiation therapy), treatment volumes at different disease stages, and principles of drug and accompanying therapy for patients with vulvar cancer. Material and Methods. The literature review was based on the clinical recommendations of the Ministry of Health of the Russian Federation and National Comprehensive Cancer Network (NCC N), as well as on the search of sources in PubMed and Cochrane Library systems. Literature sources and publications from 2005 to 2023 were included. Results. This contribution outlined the main indications for preoperative, postoperative and radical radiotherapy in patients with vulvar cancer, as well as the basic principles of drug treatment and correction of complications. Potential risk factors for postoperative disease recurrence were identified, the volumes of irradiation at each treatment mode were analyzed, and the feasibility of using brachytherapy in patients with vulvar cancer was discussed. Conclusion. To date, there are recommendations, guidelines for the management of patients with vulvar cancer, as well as clinical trial results. Understanding of the principles of prescribing treatment for vulvar cancer patients can improve local control, overall and recurrence-free survival, and the use of modern radiotherapy techniques will enshure an acceptable quality of life in these patients.
{"title":"Vulvar cancer. The contribution of radiotherapy to the treatment of the disease","authors":"P. A. Lushnikova, E. Sukhikh, Z. Startseva","doi":"10.21294/1814-4861-2024-23-3-150-158","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-150-158","url":null,"abstract":"The aim of the study was to analyze and summarize the available literature data on the modern radiotherapy techniques, indications for radiotherapy (preoperative, radical, postoperative radiation therapy), treatment volumes at different disease stages, and principles of drug and accompanying therapy for patients with vulvar cancer. Material and Methods. The literature review was based on the clinical recommendations of the Ministry of Health of the Russian Federation and National Comprehensive Cancer Network (NCC N), as well as on the search of sources in PubMed and Cochrane Library systems. Literature sources and publications from 2005 to 2023 were included. Results. This contribution outlined the main indications for preoperative, postoperative and radical radiotherapy in patients with vulvar cancer, as well as the basic principles of drug treatment and correction of complications. Potential risk factors for postoperative disease recurrence were identified, the volumes of irradiation at each treatment mode were analyzed, and the feasibility of using brachytherapy in patients with vulvar cancer was discussed. Conclusion. To date, there are recommendations, guidelines for the management of patients with vulvar cancer, as well as clinical trial results. Understanding of the principles of prescribing treatment for vulvar cancer patients can improve local control, overall and recurrence-free survival, and the use of modern radiotherapy techniques will enshure an acceptable quality of life in these patients.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141670145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-07DOI: 10.21294/1814-4861-2024-23-3-124-132
S. Panin, V. A. Suvorov, A. V. Zubkov, S. A. Bezborodov, A. A. Panina, N. V. Kovalenko, A. Donsckaia, I. G. Shushkova, A. V. Bykov, Ya. A. Marenkov
Objective. Determination of the optimal machine learning model for the creation of software for screening and early diagnosis of pancreatic neoplasms in the context of centralization of the laboratory service in the region. Material and Methods. The clinical material was based on 1254 patients who were examined in the centralized laboratory of the Volgograd Consultative and Diagnostic Polyclinic No. 2. Of these, 139 were subsequently operated on at the Volgograd Regional Clinical Oncology Dispensary for pancreatic malignancies. In 65 (46.7 %) cases, distal pancreatic resection was performed, and in 74 (53.3 %) cases, pancreaticoduodenectomy was performed. In 28 (20.1 %) cases, at the time of tumor detection, patients did not have clinical symptoms. Statistical processing of the data was carried out using the Python programming language. Five different classifiers were used for machine learning. Results. In the course of factor analysis, 11 parameters were selected from 62 laboratory blood parameters, the dynamics of changes in which should be specifically assessed at the stages of screening and early diagnosis of pancreatic neoplasms. A comparative assessment of machine learning techniques showed that the best option for creating the appropriate software was Hist Gradient Boosting (diagnostic accuracy 0.909, sensitivity 0.642, specificity 0.965, negative predictability 0.928, positive predictability 0.794, F1 0.828, logistic regression loss function 0.352, area under the ROC curve 0.89). Conclusion. The creation of software based on the selected algorithm will make it possible to clarify the real effectiveness of machine learning on a larger population of patients with pancreatic neoplasms.
{"title":"Artificial intelligence for screening and early diagnosis of pancreatic neoplasms in the context of centralization of the laboratory service in the region.","authors":"S. Panin, V. A. Suvorov, A. V. Zubkov, S. A. Bezborodov, A. A. Panina, N. V. Kovalenko, A. Donsckaia, I. G. Shushkova, A. V. Bykov, Ya. A. Marenkov","doi":"10.21294/1814-4861-2024-23-3-124-132","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-124-132","url":null,"abstract":"Objective. Determination of the optimal machine learning model for the creation of software for screening and early diagnosis of pancreatic neoplasms in the context of centralization of the laboratory service in the region. Material and Methods. The clinical material was based on 1254 patients who were examined in the centralized laboratory of the Volgograd Consultative and Diagnostic Polyclinic No. 2. Of these, 139 were subsequently operated on at the Volgograd Regional Clinical Oncology Dispensary for pancreatic malignancies. In 65 (46.7 %) cases, distal pancreatic resection was performed, and in 74 (53.3 %) cases, pancreaticoduodenectomy was performed. In 28 (20.1 %) cases, at the time of tumor detection, patients did not have clinical symptoms. Statistical processing of the data was carried out using the Python programming language. Five different classifiers were used for machine learning. Results. In the course of factor analysis, 11 parameters were selected from 62 laboratory blood parameters, the dynamics of changes in which should be specifically assessed at the stages of screening and early diagnosis of pancreatic neoplasms. A comparative assessment of machine learning techniques showed that the best option for creating the appropriate software was Hist Gradient Boosting (diagnostic accuracy 0.909, sensitivity 0.642, specificity 0.965, negative predictability 0.928, positive predictability 0.794, F1 0.828, logistic regression loss function 0.352, area under the ROC curve 0.89). Conclusion. The creation of software based on the selected algorithm will make it possible to clarify the real effectiveness of machine learning on a larger population of patients with pancreatic neoplasms.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141670610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-07DOI: 10.21294/1814-4861-2024-23-3-115-123
A. Mordovskiy, A. Aksarin, A. M. Parsadanyan, P. P. Troyan, A. I. Pakhtusov
Objective: to study the histological structure of lung cancer, as well as molecular-genetic, gender, demographic and anamnestic characteristics of patients with non-small cell lung cancer in Khanty-Mansiysk Autonomous district – Ugra. Material and Methods. Material for the study consisted of 6725 cases of lung cancer for the period 2001–2020 and 266 cases diagnosed with non-small cell lung cancer for the period 2020–2023. Nonparametric Fisher’s criterion and χ2 test were used to analyze statistical factors. The relative risk of an event in the main group compared to the control group was calculated. Results. Squamous cell carcinoma remained the most common histological form among lung cancers detected for the periods 2001–2010 and 2011–2020 (40.2 and 38.3 %, respectively). During the second decade of the study period, the proportion of lung adenocarcinoma increased by 9.6%, approaching the rates of squamous cell lung carcinoma. It should be noted that in the structure of all histologic subtypes of non-small cell lung cancer, genetic aberrations occurred more frequently in adenocarcinoma than in other histologic forms of lung cancer (33 vs 6 %, respectively). The results of the analysis showed that the relative risk of developing genetic aberrations in EGFR, KRAS, ALK oncogenes was respectively 21.08; 9.04 and 10.84 times higher in lung adenocarcinoma and 15.87; 2.18 and 10.2 times higher among never smokers than in the control groups. The incidence of mutations in the EGFR gene was statistically more frequent in women (p<0.001), and the incidence of translocation in the AL K gene was predominantly diagnosed at age ≥48 years (p=0.002) regardless of gender. The specificity of PD-L1 expression levels (low – 63.2 %, medium – 16.2 %, high – 4.5 %) is consistent with other recent studies. Conclusion. The study of molecular-genetic changes observed in patients with non-small-cell lung cancer in Ugra allows the development of organizational and methodological approaches to diagnosis and treatment of these patients.
{"title":"Histological trends and molecular genetic features of non-small cell lung cancer in the Khanty-Mansiysk autonomous district – Ugra","authors":"A. Mordovskiy, A. Aksarin, A. M. Parsadanyan, P. P. Troyan, A. I. Pakhtusov","doi":"10.21294/1814-4861-2024-23-3-115-123","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-115-123","url":null,"abstract":"Objective: to study the histological structure of lung cancer, as well as molecular-genetic, gender, demographic and anamnestic characteristics of patients with non-small cell lung cancer in Khanty-Mansiysk Autonomous district – Ugra. Material and Methods. Material for the study consisted of 6725 cases of lung cancer for the period 2001–2020 and 266 cases diagnosed with non-small cell lung cancer for the period 2020–2023. Nonparametric Fisher’s criterion and χ2 test were used to analyze statistical factors. The relative risk of an event in the main group compared to the control group was calculated. Results. Squamous cell carcinoma remained the most common histological form among lung cancers detected for the periods 2001–2010 and 2011–2020 (40.2 and 38.3 %, respectively). During the second decade of the study period, the proportion of lung adenocarcinoma increased by 9.6%, approaching the rates of squamous cell lung carcinoma. It should be noted that in the structure of all histologic subtypes of non-small cell lung cancer, genetic aberrations occurred more frequently in adenocarcinoma than in other histologic forms of lung cancer (33 vs 6 %, respectively). The results of the analysis showed that the relative risk of developing genetic aberrations in EGFR, KRAS, ALK oncogenes was respectively 21.08; 9.04 and 10.84 times higher in lung adenocarcinoma and 15.87; 2.18 and 10.2 times higher among never smokers than in the control groups. The incidence of mutations in the EGFR gene was statistically more frequent in women (p<0.001), and the incidence of translocation in the AL K gene was predominantly diagnosed at age ≥48 years (p=0.002) regardless of gender. The specificity of PD-L1 expression levels (low – 63.2 %, medium – 16.2 %, high – 4.5 %) is consistent with other recent studies. Conclusion. The study of molecular-genetic changes observed in patients with non-small-cell lung cancer in Ugra allows the development of organizational and methodological approaches to diagnosis and treatment of these patients.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141671059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-06DOI: 10.21294/1814-4861-2024-23-3-106-114
I. Khan, M. Hussain, A. Latif, A. Sarwar
Introduction. The esophagus cancer patients needs early diagnosis to achieve better prognosis. The delay barriers increase progression of diseases to higher stages. The aim of work was to identify and explore the barriers in diagnosis of esophagus cancer and chart the time duration in this process. Material and Methods. The study was conducted in Jinnah Hospital Lahore (JHL), a teaching care hospital of Allama Iqbal Medical College, during a period of one year from July 2019 to July 2020. There were 49.42 % female and 50.57 % male patients. Results. Mean age found to be 56 years. Mean Total delay (TD ) time was 206 days and median Total delay (TD ) time in days were 197 days with 25th and 75th (157, 246) percentiles respectively. Longest delays were found in 51–60 age group and age related (r=0.94) significantly to delays (p=0.0004). Initial symptom of weight loss shows maximum delay and symptoms are highly correlated (r=0.94) with delay (p=0.004). The low income group presents maximum delay. Mean patient delay (PD ) time in days were 142 days with 135 Median and (88, 195) 25th and 75th percentile respectively. Mean, Median, 25th and 75th percentiles for Physician delays (PhyD) times were (20, 18, 16, 23) respectively. Treatment delay (TD ) time (Mean, Median) in days were (18, 18.52) with 25th and 75th (14, 22) percentiles. The education significantly reduces the delays with correlation (r=0.91) and significance (p=0.02). Mean system delay (SD ) time were 25 days and median were 24 days with 25th and 75th (20, 31) percentiles. Conclusion. Illiteracy, financial problems, and unavailability of information related to the cancer and health care system, very limited number of health facilities remains the main causes of these delays.
{"title":"Factors of cancer diagnosed family and medical system for delay in diagnosis and treatment of esophageal cancer","authors":"I. Khan, M. Hussain, A. Latif, A. Sarwar","doi":"10.21294/1814-4861-2024-23-3-106-114","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-106-114","url":null,"abstract":"Introduction. The esophagus cancer patients needs early diagnosis to achieve better prognosis. The delay barriers increase progression of diseases to higher stages. The aim of work was to identify and explore the barriers in diagnosis of esophagus cancer and chart the time duration in this process. Material and Methods. The study was conducted in Jinnah Hospital Lahore (JHL), a teaching care hospital of Allama Iqbal Medical College, during a period of one year from July 2019 to July 2020. There were 49.42 % female and 50.57 % male patients. Results. Mean age found to be 56 years. Mean Total delay (TD ) time was 206 days and median Total delay (TD ) time in days were 197 days with 25th and 75th (157, 246) percentiles respectively. Longest delays were found in 51–60 age group and age related (r=0.94) significantly to delays (p=0.0004). Initial symptom of weight loss shows maximum delay and symptoms are highly correlated (r=0.94) with delay (p=0.004). The low income group presents maximum delay. Mean patient delay (PD ) time in days were 142 days with 135 Median and (88, 195) 25th and 75th percentile respectively. Mean, Median, 25th and 75th percentiles for Physician delays (PhyD) times were (20, 18, 16, 23) respectively. Treatment delay (TD ) time (Mean, Median) in days were (18, 18.52) with 25th and 75th (14, 22) percentiles. The education significantly reduces the delays with correlation (r=0.91) and significance (p=0.02). Mean system delay (SD ) time were 25 days and median were 24 days with 25th and 75th (20, 31) percentiles. Conclusion. Illiteracy, financial problems, and unavailability of information related to the cancer and health care system, very limited number of health facilities remains the main causes of these delays.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141672314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.21294/1814-4861-2024-23-3-100-105
M. Rykov, I. S. Dolgopolov
Background. Acute leukemia (AL) is the most common childhood cancer with an incidence rate of about 55–62 cases per 1 million children under 18 years of age. Acute leukemia is difficult to diagnose due to nonspecific symptoms, which are often hidden under the “masks” of other diseases. This problem is especially relevant for regions with a population of up to 100,000 people, where AL in children is diagnosed once every 2–5 years causing too low cancer alertness among pediatricians. Aim: to assess the delay in diagnosis depending on the areas of residence in the Tver region and area remoteness from the Tver Regional Clinical Children’s Hospital (RCC H). Material and Methods. The analysis included 35 patients hospitalized in the Department of Oncology and Hematology of the RCC H for the period from 2018 to 2023. The diagnoses were: ALL, C91.0 – 30 (86 %), AML , C92 – 3 (9 %), and AL of unspecified cell type (ALUCL ), C95.0 – 2 (5 %) patients. The mean age was 61 months. Thrombocytopenia and anemia at the time of diagnosis were found in 76 % and 78 %, respectively. Leukocytosis >20×109/L was observed in 58 %, leukopenia <3.5×109/L in 15 % of patients. In 97 % of cases, blasts (2 % to 95 %) were detected in peripheral blood. In the city of Tver (group 1) and the Tver region (group 2), 16 (46 %) and 19 (54 %) patients were identified, respectively. The mean age of patients in group 1 was 28.6 months and the mean age in group 2 was 72.3 months (p=0.1). Results. In group 1 and 2, ALL was diagnosed in 14 (88 %) and 16 (84 %), AML in 1 (6 %) and 2 (11 %) and ALUCL in 1 (6 %) and 1 (5 %) cases, p=0.6, 0.7 and 0.95, respectively. Delay in diagnosis in the general group (n=35) was observed <2 weeks in 21 (60 %) cases, 2–4 weeks – in 7 (20 %), ≥4–≤8 weeks – in 4 (11 %) and >8 weeks – in 3 (9 %) cases. Delayed diagnosis among patients living in the city of Tver and Tver region was observed <2 weeks in 7 (44 %) vs 13 (68 %) cases, 2–4 weeks – in 6 (38 %) vs 3 (17 %), ≥4–≤8 weeks – in 1 (6 %) vs 1 (5 %) and >8 weeks – in 2 (12 %) vs 2 (10 %) cases, respectively (p=0.37). There was no significant impact of the distance of the residence place from the level 3 children’s hospital providing specialized care (RCC H) on the time of diagnosis. With the removal of <50 km the diagnosis delay <2 weeks, 2–4 weeks, ≥4–≤8 weeks, >8 weeks was observed in 36, 36, 21 and 7 %, respectively. With the removal of ≥50–≤100 km, the diagnosis was made in the period of 2–4 weeks in 100 % of cases. With the removal of >100 km the diagnosis delay <2 weeks, 2–4 weeks, ≥4–≤8 weeks, >8 weeks was observed in 30, 30, 20 and 20 %, respectively (p=0.78). Conclusion. The distance from the third-level hospital did not affect the period of diagnosis of AL in children, which is achieved by holding daily on-line conferences with country hospitals and out-patient departments followed by the rapid hospitalization of children with suspected oncohematological disorders in the specialized department.
{"title":"Diagnosis of acute leukemia in children: the impact of remote residence on the time to make a diagnosis","authors":"M. Rykov, I. S. Dolgopolov","doi":"10.21294/1814-4861-2024-23-3-100-105","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-100-105","url":null,"abstract":"Background. Acute leukemia (AL) is the most common childhood cancer with an incidence rate of about 55–62 cases per 1 million children under 18 years of age. Acute leukemia is difficult to diagnose due to nonspecific symptoms, which are often hidden under the “masks” of other diseases. This problem is especially relevant for regions with a population of up to 100,000 people, where AL in children is diagnosed once every 2–5 years causing too low cancer alertness among pediatricians. Aim: to assess the delay in diagnosis depending on the areas of residence in the Tver region and area remoteness from the Tver Regional Clinical Children’s Hospital (RCC H). Material and Methods. The analysis included 35 patients hospitalized in the Department of Oncology and Hematology of the RCC H for the period from 2018 to 2023. The diagnoses were: ALL, C91.0 – 30 (86 %), AML , C92 – 3 (9 %), and AL of unspecified cell type (ALUCL ), C95.0 – 2 (5 %) patients. The mean age was 61 months. Thrombocytopenia and anemia at the time of diagnosis were found in 76 % and 78 %, respectively. Leukocytosis >20×109/L was observed in 58 %, leukopenia <3.5×109/L in 15 % of patients. In 97 % of cases, blasts (2 % to 95 %) were detected in peripheral blood. In the city of Tver (group 1) and the Tver region (group 2), 16 (46 %) and 19 (54 %) patients were identified, respectively. The mean age of patients in group 1 was 28.6 months and the mean age in group 2 was 72.3 months (p=0.1). Results. In group 1 and 2, ALL was diagnosed in 14 (88 %) and 16 (84 %), AML in 1 (6 %) and 2 (11 %) and ALUCL in 1 (6 %) and 1 (5 %) cases, p=0.6, 0.7 and 0.95, respectively. Delay in diagnosis in the general group (n=35) was observed <2 weeks in 21 (60 %) cases, 2–4 weeks – in 7 (20 %), ≥4–≤8 weeks – in 4 (11 %) and >8 weeks – in 3 (9 %) cases. Delayed diagnosis among patients living in the city of Tver and Tver region was observed <2 weeks in 7 (44 %) vs 13 (68 %) cases, 2–4 weeks – in 6 (38 %) vs 3 (17 %), ≥4–≤8 weeks – in 1 (6 %) vs 1 (5 %) and >8 weeks – in 2 (12 %) vs 2 (10 %) cases, respectively (p=0.37). There was no significant impact of the distance of the residence place from the level 3 children’s hospital providing specialized care (RCC H) on the time of diagnosis. With the removal of <50 km the diagnosis delay <2 weeks, 2–4 weeks, ≥4–≤8 weeks, >8 weeks was observed in 36, 36, 21 and 7 %, respectively. With the removal of ≥50–≤100 km, the diagnosis was made in the period of 2–4 weeks in 100 % of cases. With the removal of >100 km the diagnosis delay <2 weeks, 2–4 weeks, ≥4–≤8 weeks, >8 weeks was observed in 30, 30, 20 and 20 %, respectively (p=0.78). Conclusion. The distance from the third-level hospital did not affect the period of diagnosis of AL in children, which is achieved by holding daily on-line conferences with country hospitals and out-patient departments followed by the rapid hospitalization of children with suspected oncohematological disorders in the specialized department.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141674179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-04DOI: 10.21294/1814-4861-2024-23-3-86-99
A. V. Ponomarev, P. V. Tsarapaev, M. Baryshnikova, Z. A. Sokolova, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, E. Danilenko, V. Kosorukov
Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. Material and Methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG 7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180–188 with the studied adjuvants was performed in a mixed (preventive/therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG 7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180–188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry. Results. In the B16-F10 model, vaccination in a mixed mode protected mice from tumor formation, and the mice lived for more than 100 days. For B16-F10 and EG 7, vaccination in the therapeutic mode led only to inhibition of tumor growth. Ridostin Pro and Poly(I:C) showed a similar ability to develop specific immunity to the peptide TRP2 and ovalbumin. Ridostin Pro increased cytokine levels in the blood serum of mice more strongly than Poly(I:C). Both drugs caused similar changes in the immunophenotype of spleen cells, but Ridostin Pro increased the number of CD 69+ T cells more strongly than Poly(I:C). Conclusion. The comparison of two drugs as adjuvants for antitumor vaccines showed that the domestic drug Ridostin Pro did not inferior in effectiveness to Poly(I:C) on mouse models. In this regard, Ridostin Pro can be considered as a promising adjuvant for antitumor vaccines and deserves further study.
研究目的：比较抗原相同但佐剂不同的疫苗的抗肿瘤效力和免疫原性：Ridostin Pro或Poly(I:C)；评估Ridostin Pro和Poly(I:C)对血清细胞因子谱和小鼠脾脏细胞免疫表型的影响。材料与方法为了评估使用不同佐剂的疫苗的抗肿瘤效果，我们使用了两种可移植的肿瘤株：黑色素瘤 B16-F10 和 C57BL/6 小鼠的 EG 7-OVA 淋巴瘤（表达卵清蛋白）。针对黑色素瘤 B16-F10，在混合（预防/治疗）和治疗方案中使用多肽 TRP2 180-188 和所研究的佐剂进行接种。含佐剂的卵清蛋白以治疗模式接种 EG 7 淋巴瘤。使用 ELISPOT 方法评估了不同佐剂的疫苗在无肿瘤小鼠体内的免疫原性。在这种情况下，多肽 TRP2 180-188 和蛋白卵清蛋白也可作为抗原。使用流式细胞术研究了血清中细胞因子的分布情况以及小鼠脾脏细胞在服用 Ridostin Pro 或 Poly(I:C) 后免疫表型的变化。结果显示在B16-F10模型中，混合模式的疫苗接种保护小鼠免于肿瘤形成，小鼠存活时间超过100天。对于 B16-F10 和 EG 7，以治疗模式接种疫苗只能抑制肿瘤生长。Ridostin Pro 和 Poly(I:C) 对多肽 TRP2 和卵清蛋白产生特异性免疫的能力相似。Ridostin Pro比Poly(I:C)更能提高小鼠血清中的细胞因子水平。这两种药物对脾脏细胞免疫表型的改变相似，但利多司汀 Pro 对 CD 69+ T 细胞数量的增加作用比聚(I:C)更强。结论两种药物作为抗肿瘤疫苗佐剂的比较结果表明，国产药物 Ridostin Pro 在小鼠模型上的效果并不逊色于 Poly(I:C)。因此，Ridostin Pro 可被视为一种很有前景的抗肿瘤疫苗佐剂，值得进一步研究。
{"title":"Study of Ridostin Pro and Poly(I:C) as adjuvants that enhance the immunogenicity of an antitumor vaccine","authors":"A. V. Ponomarev, P. V. Tsarapaev, M. Baryshnikova, Z. A. Sokolova, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, E. Danilenko, V. Kosorukov","doi":"10.21294/1814-4861-2024-23-3-86-99","DOIUrl":"https://doi.org/10.21294/1814-4861-2024-23-3-86-99","url":null,"abstract":"Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. Material and Methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG 7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180–188 with the studied adjuvants was performed in a mixed (preventive/therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG 7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180–188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry. Results. In the B16-F10 model, vaccination in a mixed mode protected mice from tumor formation, and the mice lived for more than 100 days. For B16-F10 and EG 7, vaccination in the therapeutic mode led only to inhibition of tumor growth. Ridostin Pro and Poly(I:C) showed a similar ability to develop specific immunity to the peptide TRP2 and ovalbumin. Ridostin Pro increased cytokine levels in the blood serum of mice more strongly than Poly(I:C). Both drugs caused similar changes in the immunophenotype of spleen cells, but Ridostin Pro increased the number of CD 69+ T cells more strongly than Poly(I:C). Conclusion. The comparison of two drugs as adjuvants for antitumor vaccines showed that the domestic drug Ridostin Pro did not inferior in effectiveness to Poly(I:C) on mouse models. In this regard, Ridostin Pro can be considered as a promising adjuvant for antitumor vaccines and deserves further study.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141679434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：